Advertisement

Topics

ViiV hails data showing switch from Truvada to two-drug HIV regimen

08:43 EDT 10 Jul 2019 | pharmaphorum

ViiV is continuing its assault on arch-rival Gilead in HIV, with phase 3 results aimed at giving doctors confidence that patients can switch from rival triple therapies to its new two-drug regimen. ViiV, a joint venture between majority owner Glax...

Original Article: ViiV hails data showing switch from Truvada to two-drug HIV regimen

NEXT ARTICLE

More From BioPortfolio on "ViiV hails data showing switch from Truvada to two-drug HIV regimen"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...